Geovax Labs Inc
Company Profile
Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Contact
1955 Lake Park Drive
Suite 300
SmyrnaGA30080
USAT: +1 678 384-7220
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 6.60 | 0.07% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,498.64 | 138.37 | -0.26% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 24,213.72 | 38.60 | 0.16% |
| NASDAQ | 25,873.18 | 408.43 | -1.55% |
| Nikkei 225 | 67,242.73 | 1,315.00 | -1.92% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,515.34 | 60.05 | -0.79% |
| S&P/ASX 200 | 8,808.50 | 11.70 | 0.13% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |